Simultaneous Activation of Immunogenic Cell Death and cGAS-STING Pathway by Liver- and Mitochondria-Targeted Gold(I) Complexes for Chemoimmunotherapy of Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Simultaneous Activation of Immunogenic Cell Death and cGAS-STING Pathway by Liver- and Mitochondria-Targeted Gold(I) Complexes for Chemoimmunotherapy of Hepatocellular Carcinoma

Published:2024-01-23 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Fuwei¹,Wen Zhenfan¹,Wu Chuanxing²,Yang Zhibin³,Wang Zhaoran¹,Diao Wenjing⁴,Chen Dahong⁴,Xu Zhongren¹,Lu Yunlong¹⁵,Liu Wukun¹⁵^ORCID

Affiliation:

1. Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China

2. Department of General Surgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai 210011, P. R. China

3. Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, Dali University, Dali 671000, P. R. China

4. Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 210011, P. R. China

5. State Key Laboratory of Coordination Chemistry, Nanjing University, Nanjing 210023, P. R. China

Funder

Graduate Research and Innovation Projects of Jiangsu Province

Nanjing University of Chinese Medicine

High Level Innovation and Entrepreneurial Research Team Program in Jiangsu

State Administration of Traditional Chinese Medicine of the People's Republic of China

Jiangsu Provincial Department of Science and Technology

National Natural Science Foundation of China

State Key Laboratory of Coordination Chemistry

Priority Academic Program Development of Jiangsu Higher Education Institutions

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01785

Reference82 articles.

1. Hepatocellular carcinoma

2. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

3. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

4. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

5. Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials